Analysts predict that Celsion Co. (NASDAQ:CLSN) will report sales of $130,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Celsion’s earnings. Celsion also reported sales of $130,000.00 in the same quarter last year. The company is scheduled to issue its next earnings report on Thursday, March 15th.
On average, analysts expect that Celsion will report full year sales of $130,000.00 for the current fiscal year. For the next financial year, analysts anticipate that the company will post sales of $500,000.00 per share. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Celsion.
Celsion (NASDAQ:CLSN) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.17. Celsion had a negative return on equity of 282.94% and a negative net margin of 4,292.80%. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million.
An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC acquired a new stake in shares of Celsion Co. (NASDAQ:CLSN) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned approximately 0.24% of Celsion at the end of the most recent quarter. 3.63% of the stock is currently owned by institutional investors and hedge funds.
Celsion (CLSN) opened at $2.21 on Thursday. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06. The firm has a market capitalization of $35.50, a price-to-earnings ratio of -0.38 and a beta of 1.81.
ILLEGAL ACTIVITY NOTICE: “Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/15/analysts-expect-celsion-co-clsn-will-announce-quarterly-sales-of-130000-00.html.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.